A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. - Wikidata - wikimedia - TriplyDB

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.

http://www.wikidata.org/entity/Q45882197

about

Megakaryocyte- and megakaryocyte precursor-related gene therapies Emerging and future therapies for hemophilia Future of coagulation factor replacement therapy Improving biophysical properties of a bispecific antibody scaffold to aid developability Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins Gene therapy for hemophilia Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity In vitro and In vivo Model Systems for Hemophilia A Gene Therapy.A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening Molecular approaches for improved clotting factors for hemophilia.Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A.Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.Blood Clotting Factor VIII: From Evolution to Therapy.Novel products for haemostasis - current status.Novel products for haemostasis.Novel therapeutic approaches for haemophilia.Longer-acting clotting factor concentrates for hemophilia.New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.New products for the treatment of haemophilia.Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A.The utility of thromboelastography in inherited and acquired bleeding disorders.The use of CrossMAb technology for the generation of bi- and multispecific antibodies.2017 Clinical trials update: Innovations in hemophilia therapy.Advances in the treatment of bleeding disorders.Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.Production of recombinant coagulation factors: Are humans the best host cells?VHH-Based Bispecific Antibodies Targeting Cytokine Production Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry.Non-antigen-contacting region of an asymmetric bispecific antibody to factors IXa/X significantly affects factor VIII-mimetic activity.A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation.Novel approaches to hemophilia therapy: successes and challenges.A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A.A complex substitute: antibody therapy for hemophilia.Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.

P2860

Q26770867-DA95963B-ADC4-48DF-A99F-77E596AACDB1 Q26781143-8830CE21-5D23-424B-8788-BB8E28281A28 Q26820824-103EF94E-D513-4D42-87C5-A97E16F5F490 Q27679445-F6C79153-2E35-46E4-925E-E9E53568ED74 Q28072319-0F42506C-169A-457E-A700-430F3F40B930 Q28081911-547517FD-8990-46BD-BE62-6172C90AF42B Q28487387-BD9DD1F1-3BA8-4961-8FE4-C558B96A2719 Q34499850-1AC18A5A-85E9-46E8-A699-947794A2AAA2 Q34503723-25B3BB09-4E44-469F-9DDD-2CACBF5A5C9F Q35119802-9868B084-F48D-41A9-BB6E-30EBBAEABC0F Q35565320-FF6E1880-90F0-4294-8AC8-69E2164817C8 Q35870955-6A502DEF-76D6-4839-BB6C-38A695550221 Q37334700-58EF919A-CBC0-45D8-81B0-C0D9BD6A9902 Q37403833-A8F74989-7623-4FC8-9264-A2861A02433F Q37484229-D7C44897-6DDC-48DC-B678-25E42AC8B40C Q38118763-515EA8F6-53BB-4BC8-93DF-52534F7E8C02 Q38206849-A28EF0F0-6066-42A3-BCEC-19B461D14250 Q38206850-B5651C80-CC5B-4721-BFCC-BBE51F1D9B94 Q38293116-38ECC538-CA0A-471D-9169-AAB5C1052367 Q38543283-BF45727B-B7AF-40B8-8099-604327B9913B Q38574414-79B543EF-886C-478F-8893-DD52CADB2F77 Q38604626-F31ECB93-97D4-49CD-BC62-A203A3315214 Q38828174-39771880-12DA-452E-92BA-D17B5310B60B Q38855599-E61A9645-FA40-42B1-9895-6E7C69828150 Q38861238-454ACC1E-DBFE-4ABC-8061-4CCD76663019 Q38937725-0F2CBDD4-1FE2-45D9-89CF-B86F5AEC04FF Q38945123-D49B1C41-ED32-49CC-A636-2BF30B3B1B28 Q38951490-E722A996-5004-4E2F-A93D-DCF37495D9F0 Q39170433-E29E987F-2FDE-4533-9E8C-FE162A56DE59 Q41619629-930D0EC5-971B-46C7-A6E0-72D3E18DD930 Q41864920-5D87F649-2BE0-4D30-A364-F4266E6FDB46 Q42076342-78F6C897-FEE1-4F81-889D-FECF739EEF11 Q42128614-80FDDDA5-3872-4E1D-900B-7304E4F74E58 Q44051815-1E26CD11-A0A0-4BFF-91D6-437FDCC07690 Q45864199-FF433851-5ECF-4CBC-9F09-471E0A4B0170 Q45873013-65F7A85C-9A2B-4707-8071-719E3EA433CF Q45875541-8C245FA4-3249-4C22-AE25-58DEF61A7D51 Q45882338-27AFA75D-1389-469F-A3D2-C0C83A300A7E Q46866013-3E51E840-84FA-402C-8BA8-0429ADDD517A Q47594827-2D233158-06B6-45E8-B904-029E685D6003

P2860

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.

http://www.wikidata.org/entity/Q45882197

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

A bispecific antibody to facto ...... ivity in a hemophilia A model.

@en

A bispecific antibody to facto ...... ivity in a hemophilia A model.

@nl

type

label

A bispecific antibody to facto ...... ivity in a hemophilia A model.

@en

A bispecific antibody to facto ...... ivity in a hemophilia A model.

@nl

prefLabel

A bispecific antibody to facto ...... ivity in a hemophilia A model.

@en

A bispecific antibody to facto ...... ivity in a hemophilia A model.

@nl

P1433

Q45882197-573E191C-BE52-4BA6-B714-F79DCB0680B3

P1476

Q45882197-4C751CAB-0D13-42F9-A6C6-03AFCE5C9AE5

P2093

Q45882197-0E231864-CAEB-46EC-85AC-6384A2AB98B2

Q45882197-1035CAA0-94EF-4AD7-AD79-1AF86DBC9362

Q45882197-1C0F4A7E-2BA7-47BD-AB7B-65230AA0CF86

Q45882197-43DAB38C-9F6E-4205-AC76-DDE97C6C3CE4

Q45882197-46984B8D-EA4F-4EF5-A4EB-F634D820AAAD

Q45882197-4C898723-DAD3-4F67-A551-E39AC99DBF3E

Q45882197-4DBD746C-AE40-4388-9C85-2213EFD4FEB3

Q45882197-4DBFFAE2-1253-4A9E-8365-5C69883F05B5

Q45882197-4E4DE7AD-1AB9-4B7D-AB44-E11472C1C6DE

Q45882197-5577F63A-3068-410C-8091-81CA8D64A580

P2860

Q45882197-00BCF3C4-2A23-4D8B-9513-0131E2608615

Q45882197-0AB5181E-1B59-4028-8BFE-7E65EB1B45A6

Q45882197-0D588717-1726-4816-8155-862AFD6DCF7C

Q45882197-137A0073-2BCE-4609-88B7-96C90030E9C7

Q45882197-1E43A1BB-8073-4A81-ABE7-B4644BFFFACE

Q45882197-1FF7D619-501A-4338-8972-F5CD8CCDDAAF

Q45882197-2D0D6143-4BB4-4894-9D08-7A90D0F0341B

Q45882197-30451398-5A3D-4D34-95FB-CBF837C3D70B

Q45882197-314AC5F7-CF92-4DD1-A606-28A2D10C691E

Q45882197-38E052C7-E77E-4D57-B2C0-85B43C77213D

P2888

Q45882197-21AAFD11-1BDE-4611-B039-50078548E40D

P304

Q45882197-9B3B35CA-4F25-4C05-9E1A-7FCC6F8C11F0

P31

Q45882197-D4B8A668-B7E8-4F92-806E-7A331F7C7602

P356

Q45882197-E00982CC-0B86-4EB8-9BB0-8A211B90D8BD

P407

Q45882197-293A0FBF-3E89-4A31-8386-BF409064A4F0

P433

Q45882197-DA8536B2-9BC5-4230-AC2A-BB636F73C9D8

P478

Q45882197-B142CBC1-F79F-4E11-B482-E6F1C430A018

P577

Q45882197-1C0C24C3-0957-4786-BC22-C067D22B8DEF

P5875

Q45882197-8C5E029B-5EE8-4D65-AD51-E2C81D03EB20

P6179

Q45882197-5E1C5A46-1E56-4136-9458-9F5B5BF42A16

P698

Q45882197-DB330B3F-8EE6-4A47-B027-75690A7FC7C4

P921

Q45882197-57453026-003A-49F8-A561-0B1ACB5A8BF8

Q45882197-E95C8D97-D3AF-4F56-A05B-12FBBA1530C1

Q45882197-FBBCEB6B-D348-4804-A187-4C4353CF91D4

Q45882197-FC8CA9E1-FDC6-4519-BA9B-C7C66348E735

P356

P1433

Nature Medicine

P1476

A bispecific antibody to facto ...... ivity in a hemophilia A model.

@en

P2093

Akira Yoshioka

http://www.w3.org/2001/XMLSchema#string

Atsunori Ueyama

http://www.w3.org/2001/XMLSchema#string

Atsushi Muto

http://www.w3.org/2001/XMLSchema#string

Aya Harada

http://www.w3.org/2001/XMLSchema#string

Chifumi Moriyama

http://www.w3.org/2001/XMLSchema#string

Eriko Tanaka

http://www.w3.org/2001/XMLSchema#string

Hideki Adachi

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Saito

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Tsunoda

http://www.w3.org/2001/XMLSchema#string

Kazutaka Yoshihashi

http://www.w3.org/2001/XMLSchema#string

P2860

Immunogenicity of protein therapeutics: The key causes, consequences and challenges

A potent erythropoietin-mimicking human antibody interacts through a novel binding site

The tertiary structure and domain organization of coagulation factor VIII

Calibrated automated thrombin generation measurement in clotting plasma

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

Replacing the complementarity-determining regions in a human antibody with those from a mouse

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

An efficient route to human bispecific IgG.

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?

Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.

P2888

P304

1570-1574

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.2942

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

231613174

http://www.w3.org/2001/XMLSchema#string

P6179

1046646584

http://www.w3.org/2001/XMLSchema#string

P698

23023498

http://www.w3.org/2001/XMLSchema#string

P921

Coagulation factor VIII